Company intelligence / Profile preview
Iaso Therapeutics
East Lansing, Michigan, United Statesiasotherapeutics.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Developing a disruptive new virus-like particle technology (mutant Qβ) that shows superiority in generating antibodies of interest compared to traditional conjugate carrier proteins
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Vaccinesvirus-like particles
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
Fina Biosolutions (sells their mQβ product)
Beyond the preview
Go deeper on Iaso Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Iaso Therapeutics.